Engineering Delivery Vehicles for Genome Editing.

The field of genome engineering has created new possibilities for gene therapy, including improved animal models of disease, engineered cell therapies, and in vivo gene repair. The most significant challenge for the clinical translation of genome engineering is the development of safe and effective delivery vehicles. A large body of work has applied genome engineering to genetic modification in vitro, and clinical trials have begun using cells modified by genome editing. Now, promising preclinical work is beginning to apply these tools in vivo. This article summarizes the development of genome engineering platforms, including meganucleases, zinc finger nucleases, TALENs, and CRISPR/Cas9, and their flexibility for precise genetic modifications. The prospects for the development of safe and effective viral and nonviral delivery vehicles for genome editing are reviewed, and promising advances in particular therapeutic applications are discussed.

[1]  J. Keith Joung,et al.  731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .

[2]  Lixia Zhao,et al.  CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Dongsheng Duan,et al.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy , 2016, Science.

[4]  George M. Church,et al.  In vivo gene editing in dystrophic mouse muscle and muscle stem cells , 2016, Science.

[5]  John M. Shelton,et al.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy , 2016, Science.

[6]  J. Joung,et al.  High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets , 2015, Nature.

[7]  David A. Scott,et al.  Rationally engineered Cas9 nucleases with improved specificity , 2015, Science.

[8]  Luigi Naldini,et al.  Gene therapy returns to centre stage , 2015, Nature.

[9]  Y. Doyon,et al.  In vivo genome editing of the albumin locus as a platform for protein replacement therapy. , 2015, Blood.

[10]  Charles A Gersbach,et al.  Enabling functional genomics with genome engineering , 2015, Genome research.

[11]  B. Cullen,et al.  Expression of CRISPR/Cas single guide RNAs using small tRNA promoters , 2015, RNA.

[12]  A. Regev,et al.  Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System , 2015, Cell.

[13]  Matthew C. Canver,et al.  BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis , 2015, Nature.

[14]  M. Nesbit,et al.  CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting , 2015, Gene Therapy.

[15]  Jennifer A. Doudna,et al.  Generation of knock-in primary human T cells using Cas9 ribonucleoproteins , 2015, Proceedings of the National Academy of Sciences.

[16]  Israel Steinfeld,et al.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.

[17]  Daniel G. Anderson,et al.  Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. , 2015, Human gene therapy.

[18]  B. Cullen,et al.  Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. , 2015, Virology.

[19]  Lei Zhang,et al.  Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. , 2015, Blood.

[20]  Christopher M. Vockley,et al.  Epigenome editing by a CRISPR/Cas9-based acetyltransferase activates genes from promoters and enhancers , 2015, Nature Biotechnology.

[21]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[22]  Jun S. Song,et al.  Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis , 2015, Cell.

[23]  Lukas E Dow,et al.  Inducible in vivo genome editing with CRISPR/Cas9 , 2015, Nature Biotechnology.

[24]  Florian Schmidt,et al.  CRISPR genome engineering and viral gene delivery: A case of mutual attraction , 2015, Biotechnology journal.

[25]  Randall J. Platt,et al.  Therapeutic genome editing: prospects and challenges , 2015, Nature Medicine.

[26]  William H. Majoros,et al.  Multiplex CRISPR/Cas9-Based Genome Editing for Correction of Dystrophin Mutations that Cause Duchenne Muscular Dystrophy , 2015, Nature Communications.

[27]  A. Hajitou,et al.  Bacteriophage-Derived Vectors for Targeted Cancer Gene Therapy , 2015, Viruses.

[28]  William H. Majoros,et al.  Correction of Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients Through Genomic Excision of Exon 51 by Zinc Finger Nucleases , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[30]  S. Yamanaka,et al.  Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9 , 2014, Stem cell reports.

[31]  J. Keith Joung,et al.  Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2014, Nature Biotechnology.

[32]  Feng Zhang,et al.  In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9 , 2014, Nature Biotechnology.

[33]  Timothy K Lu,et al.  Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases , 2014, Nature Biotechnology.

[34]  Robert Langer,et al.  CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling , 2014, Cell.

[35]  Daniel J. Rader,et al.  Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing , 2014, Circulation research.

[36]  Philip D. Gregory,et al.  Reactivation of Developmentally Silenced Globin Genes by Forced Chromatin Looping , 2014, Cell.

[37]  Charles A. Gersbach,et al.  Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector , 2014, Nucleic acids research.

[38]  B. Cullen,et al.  Inactivation of the Human Papillomavirus E6 or E7 Gene in Cervical Carcinoma Cells by Using a Bacterial CRISPR/Cas RNA-Guided Endonuclease , 2014, Journal of Virology.

[39]  Ding-Shinn Chen,et al.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo , 2014, Molecular therapy. Nucleic acids.

[40]  Fan Yang,et al.  RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection , 2014, Proceedings of the National Academy of Sciences.

[41]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[42]  Annemieke Aartsma-Rus,et al.  Antisense-mediated exon skipping: taking advantage of a trick from Mother Nature to treat rare genetic diseases. , 2014, Experimental cell research.

[43]  Hao Yin,et al.  CRISPR-mediated direct mutation of cancer genes in the mouse liver , 2014, Nature.

[44]  Matthew C. Canver,et al.  Characterization of Genomic Deletion Efficiency Mediated by Clustered Regularly Interspaced Palindromic Repeats (CRISPR)/Cas9 Nuclease System in Mammalian Cells*♦ , 2014, The Journal of Biological Chemistry.

[45]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[46]  C. Barbas,et al.  Synthetic Zinc Finger Proteins: The Advent of Targeted Gene Regulation and Genome Modification Technologies , 2014, Accounts of chemical research.

[47]  M. van der Burg,et al.  Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.

[48]  N. Corbi,et al.  Novel Adeno-Associated Viral Vector Delivering the Utrophin Gene Regulator Jazz Counteracts Dystrophic Pathology in mdx Mice , 2014, Journal of cellular physiology.

[49]  David V. Schaffer,et al.  Engineering adeno-associated viruses for clinical gene therapy , 2014, Nature Reviews Genetics.

[50]  Yujia Cai,et al.  Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases , 2014, eLife.

[51]  Shiyou Zhu,et al.  High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells , 2014, Nature.

[52]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[53]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[54]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[55]  R. Doms,et al.  Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. , 2014, Blood.

[56]  Yilong Li,et al.  Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library , 2013, Nature Biotechnology.

[57]  R. Polishchuk,et al.  Effective delivery of large genes to the retina by dual AAV vectors , 2013, EMBO molecular medicine.

[58]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[59]  Y. Doyon,et al.  Robust ZFN-mediated genome editing in adult hemophilic mice. , 2013, Blood.

[60]  Matthew C. Canver,et al.  An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level , 2013, Science.

[61]  Chady H Hakim,et al.  Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. , 2013, Human molecular genetics.

[62]  Ronald A. Li,et al.  Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction , 2013, Nature Biotechnology.

[63]  R. Samulski,et al.  Engraftment of a Galactose Receptor Footprint onto Adeno-associated Viral Capsids Improves Transduction Efficiency* , 2013, The Journal of Biological Chemistry.

[64]  George Church,et al.  Optimization of scarless human stem cell genome editing , 2013, Nucleic acids research.

[65]  Morgan L. Maeder,et al.  CRISPR RNA-guided activation of endogenous human genes , 2013, Nature Methods.

[66]  Christopher M. Vockley,et al.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors , 2013, Nature Methods.

[67]  T. Cathomen,et al.  Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[69]  K. High,et al.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy. , 2013, Blood.

[70]  James M. Wilson,et al.  CpG-depleted adeno-associated virus vectors evade immune detection. , 2013, The Journal of clinical investigation.

[71]  Randall J. Platt,et al.  Optical Control of Mammalian Endogenous Transcription and Epigenetic States , 2013, Nature.

[72]  C. Barbas,et al.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.

[73]  Rafael J. Yáñez-Muñoz,et al.  Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in. , 2013, Human gene therapy.

[74]  Charles A Gersbach,et al.  Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[75]  Rudolf Jaenisch,et al.  One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.

[76]  J. Rousseau,et al.  Targeted Gene Addition of Microdystrophin in Mice Skeletal Muscle via Human Myoblast Transplantation , 2013, Molecular therapy. Nucleic acids.

[77]  T. Cathomen,et al.  Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells , 2012, Nucleic acids research.

[78]  K. Gruber.  Europe gives gene therapy the green light , 2012, The Lancet.

[79]  P. Glazer,et al.  Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo , 2012, Gene Therapy.

[80]  Carlos F. Barbas,et al.  Chimeric TALE recombinases with programmable DNA sequence specificity , 2012, Nucleic acids research.

[81]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[82]  E. Rebar,et al.  A Designed Zinc-finger Transcriptional Repressor of Phospholamban Improves Function of the Failing Heart , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[83]  Leaf Huang,et al.  In vivo gene delivery by nonviral vectors: overcoming hurdles? , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  C. Barbas,et al.  Targeted gene knockout by direct delivery of ZFN proteins , 2012, Nature Methods.

[85]  S. W. Kim,et al.  Evolution of oncolytic adenovirus for cancer treatment. , 2012, Advanced drug delivery reviews.

[86]  J. Seto,et al.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors. , 2012, Current gene therapy.

[87]  Krzysztof Matyjaszewski,et al.  Atom Transfer Radical Polymerization (ATRP): Current Status and Future Perspectives , 2012 .

[88]  Larry R. Smith,et al.  A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. , 2012, The Lancet. Infectious diseases.

[89]  P. Stayton,et al.  Diblock copolymers with tunable pH transitions for gene delivery. , 2012, Biomaterials.

[90]  Mark E. Davis,et al.  Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane , 2012, Proceedings of the National Academy of Sciences.

[91]  A. Bogdanove,et al.  TAL Effectors: Customizable Proteins for DNA Targeting , 2011, Science.

[92]  O. Danos,et al.  Efficient gene targeting mediated by a lentiviral vector-associated meganuclease , 2011, Nucleic acids research.

[93]  F. Bushman,et al.  In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.

[94]  Daniel G. Anderson,et al.  Silencing or stimulation? siRNA delivery and the immune system. , 2011, Annual review of chemical and biomolecular engineering.

[95]  Stan J. J. Brouns,et al.  Evolution and classification of the CRISPR–Cas systems , 2011, Nature Reviews Microbiology.

[96]  Kit S Lam,et al.  The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. , 2011, Biomaterials.

[97]  M. Kay.  State-of-the-art gene-based therapies: the road ahead , 2011, Nature Reviews Genetics.

[98]  Kyle A. Barlow,et al.  A TALE nuclease architecture for efficient genome editing , 2011, Nature Biotechnology.

[99]  G. Church,et al.  Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. , 2011, Nature biotechnology.

[100]  J. Rosenecker,et al.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice , 2011, Nature Biotechnology.

[101]  J. Vogel,et al.  CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III , 2011, Nature.

[102]  P. Duchateau,et al.  Meganucleases and Other Tools for Targeted Genome Engineering: Perspectives and Challenges for Gene Therapy , 2011, Current gene therapy.

[103]  B. Stoddard,et al.  Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modification. , 2011, Structure.

[104]  E. Rebar,et al.  Genome editing with engineered zinc finger nucleases , 2010, Nature Reviews Genetics.

[105]  Vanessa Taupin,et al.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.

[106]  D. Persons.  Lentiviral vector gene therapy: effective and safe? , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[107]  D. Dykxhoorn,et al.  Breaking down the barriers: siRNA delivery and endosome escape , 2010, Journal of Cell Science.

[108]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[109]  Jana L Phillips,et al.  Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle , 2010, Nature Biotechnology.

[110]  Matthew J. Moscou,et al.  A Simple Cipher Governs DNA Recognition by TAL Effectors , 2009, Science.

[111]  Jens Boch,et al.  Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors , 2009, Science.

[112]  S. Perrier,et al.  Bioapplications of RAFT polymerization. , 2009, Chemical reviews.

[113]  Da-Zhi Wang,et al.  A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection , 2009, Proceedings of the National Academy of Sciences.

[114]  D. Benoit,et al.  Development of a novel endosomolytic diblock copolymer for siRNA delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[115]  Shondra M. Pruett-Miller,et al.  Attenuation of Zinc Finger Nuclease Toxicity by Small-Molecule Regulation of Protein Levels , 2009, PLoS genetics.

[116]  K. Leong,et al.  Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[117]  M. Behlke.  Chemical modification of siRNAs for in vivo use. , 2008, Oligonucleotides.

[118]  Stan J. J. Brouns,et al.  Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes , 2008, Science.

[119]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[120]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[121]  N. Sharpless,et al.  Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[122]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[123]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[124]  David N Sheppard,et al.  CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression , 2008, Nature Biotechnology.

[125]  Dexi Liu,et al.  Hydrodynamic gene delivery: its principles and applications. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[126]  Luigi Naldini,et al.  Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.

[127]  Simone Hahn,et al.  A Bacterial Effector Acts as a Plant Transcription Factor and Induces a Cell Size Regulator , 2007, Science.

[128]  Simone Hahn,et al.  Plant Pathogen Recognition Mediated by Promoter Activation of the Pepper Bs3 Resistance Gene , 2007, Science.

[129]  D. Lauffenburger,et al.  Combinatorial Modification of Degradable Polymers Enables Transfection of Human Cells Comparable to Adenovirus , 2007 .

[130]  Lonnie D Shea,et al.  Matrices and scaffolds for DNA delivery in tissue engineering. , 2007, Advanced drug delivery reviews.

[131]  Torbjörn Gräslund,et al.  Evolution of programmable zinc finger-recombinases with activity in human cells. , 2007, Journal of molecular biology.

[132]  R. Barrangou,et al.  CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes , 2007, Science.

[133]  Fyodor D Urnov,et al.  Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases , 2007, Proceedings of the National Academy of Sciences.

[134]  T. Rando.  Non-viral gene therapy for Duchenne muscular dystrophy: progress and challenges. , 2007, Biochimica et biophysica acta.

[135]  Samir Mitragotri,et al.  Understanding intracellular transport processes pertinent to synthetic gene delivery via stochastic simulations and sensitivity analyses. , 2007, Biophysical journal.

[136]  Barry L. Stoddard,et al.  Homing endonuclease I-CreI derivatives with novel DNA target specificities , 2006, Nucleic acids research.

[137]  R. Samulski,et al.  Adeno-associated virus serotypes: vector toolkit for human gene therapy. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[138]  Shubiao Zhang,et al.  Toxicity of cationic lipids and cationic polymers in gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[139]  Xiao-Jin Yu,et al.  Transient gene expression by nonintegrating lentiviral vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[140]  K. Leong,et al.  Chitosan nanoparticles for oral drug and gene delivery , 2006, International journal of nanomedicine.

[141]  D. Baker,et al.  Computational redesign of endonuclease DNA binding and cleavage specificity , 2006, Nature.

[142]  B. Fehse,et al.  Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. , 2006, Human gene therapy.

[143]  D. Schaffer,et al.  Directed evolution of adeno-associated virus yields enhanced gene delivery vectors , 2006, Nature Biotechnology.

[144]  David R. Liu,et al.  Directed evolution and substrate specificity profile of homing endonuclease I-SceI. , 2006, Journal of the American Chemical Society.

[145]  P. Duchateau,et al.  Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets. , 2006, Journal of molecular biology.

[146]  Francis C Szoka,et al.  Designing dendrimers for biological applications , 2005, Nature Biotechnology.

[147]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[148]  R. Langer,et al.  Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis , 2005, The journal of gene medicine.

[149]  H. Lipps,et al.  Towards safe, non-viral therapeutic gene expression in humans , 2005, Nature Reviews Genetics.

[150]  Bing Wang,et al.  Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart , 2005, Nature Biotechnology.

[151]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[152]  R. Samulski,et al.  Integration of adeno-associated virus (AAV) and recombinant AAV vectors. , 2004, Annual review of genetics.

[153]  N. Bessis,et al.  Immune responses to gene therapy vectors: influence on vector function and effector mechanisms , 2004, Gene therapy.

[154]  D. Weissman,et al.  Small Interfering RNAs Mediate Sequence-Independent Gene Suppression and Induce Immune Activation by Signaling through Toll-Like Receptor 31 , 2004, The Journal of Immunology.

[155]  S. Akira,et al.  Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 , 2004, Science.

[156]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[157]  Aram Akopian,et al.  Chimeric recombinases with designed DNA sequence recognition , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[158]  M. Weitzman,et al.  Efficient Gene Targeting Mediated by Adeno-Associated Virus and DNA Double-Strand Breaks , 2003, Molecular and Cellular Biology.

[159]  Tatiana Segura,et al.  Surface-tethered DNA complexes for enhanced gene delivery. , 2002, Bioconjugate chemistry.

[160]  C. Pichon,et al.  Histidine-rich peptides and polymers for nucleic acids delivery. , 2001, Advanced drug delivery reviews.

[161]  R. Vile,et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[162]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[163]  C. Barbas,et al.  Positive and negative regulation of endogenous genes by designed transcription factors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[164]  David J. Mooney,et al.  DNA delivery from polymer matrices for tissue engineering , 1999, Nature Biotechnology.

[165]  G. Merlo,et al.  Polyethylenimine-based intravenous delivery of transgenes to mouse lung , 1998, Gene Therapy.

[166]  M. Ogris,et al.  Polylysine-based transfection systems utilizing receptor-mediated delivery. , 1998, Advanced drug delivery reviews.

[167]  D J Segal,et al.  Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[168]  S Chandrasegaran,et al.  Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[169]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[170]  M. Hashida,et al.  The Fate of Plasmid DNA After Intravenous Injection in Mice: Involvement of Scavenger Receptors in Its Hepatic Uptake , 1995, Pharmaceutical Research.

[171]  P. Rouet,et al.  Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. , 1994, Molecular and cellular biology.

[172]  N. Pavletich,et al.  Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A , 1991, Science.

[173]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[174]  B. Dujon,et al.  Universal code equivalent of a yeast mitochondrial intron reading frame is expressed into E. coli as a specific double strand endonuclease , 1986, Cell.

[175]  Steve Cunningham,et al.  Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial , 2015 .

[176]  N. Bresolin,et al.  Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. , 2014, Clinical therapeutics.

[177]  F. Gleason,et al.  Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA , 2014 .

[178]  K. Rapti,et al.  Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[179]  Yoshio Kato,et al.  targeted gene knockout by direct delivery of zinc-finger nuclease proteins , 2012 .

[180]  Zhaozhong Jiang,et al.  Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. , 2011, Nature materials.

[181]  P. Linsley,et al.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.

[182]  Zhijian Wu,et al.  Effect of genome size on AAV vector packaging. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[183]  P. Kuppen,et al.  Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells , 2000, Gene Therapy.

[184]  C. Pabo,et al.  DNA recognition by Cys2His2 zinc finger proteins. , 2000, Annual review of biophysics and biomolecular structure.

[185]  Scot A. Wolfe,et al.  DNA RECOGNITION BY Cys 2 His 2 ZINC FINGER PROTEINS , 2000 .

[186]  K. Musunuru,et al.  Permanent Alteration of PCSK 9 With In Vivo CRISPR-Cas 9 Genome Editing , 2022 .

[187]  Xian-Yang Zhang,et al.  LSU Digital Commons LSU Digital Commons Altering the tropism of lentiviral vectors through pseudotyping Altering the tropism of lentiviral vectors through pseudotyping , 2022 .